ClinicalTrials.gg
CompletedNCT02856919BR14004Updated Apr 6, 2017

A Multicenter, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Once Daily Mirvaso® Gel in Patients With Chronic Persistent Vascular Facial Erythema.

A Phase 4 interventional study of brimonidine tartrate in Chronic Persistent Vascular Facial Erythema, sponsored by Galderma Brasil Ltda.. Completed at 5 sites in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-04-06.

Sponsored by Galderma Brasil Ltda. (part of Galderma Group AG) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
101
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study evaluates the efficacy of Mirvaso® in the treatment of chronic persistent vascular facial erythema, after 4 weeks of treatment, by the Clinician erythema assessment.

Read the detailed description

This is a multicenter, open-label trial in research participants with chronic persistent vascular facial erythema. All eligible research participants will receive Mirvaso® gel once daily for 4 weeks, and then will be followed-up for another 2 weeks.

The study will include 4 clinical visits: before Day 1, on Day 1, Day 29 and Week 6.

Within 5 days before Day 1, the research participant will have a screening visit for confirmation of eligibility.

On Day 1 and on Day 29, the research participant will have Mirvaso® gel applied, at the research site, and the evaluation will be conducted before application and 3 hours after application; During Days 2-28, research participants will have Mirvaso® gel applied once daily, at home; On Week 6, the research participants will go back to the research site for evaluation. No Mirvaso® gel will be applied after the visit on Day 29; Unscheduled visits may be performed during the trial for any safety reason.

02

Conditions studied

  • Chronic Persistent Vascular Facial Erythema

Browse trials for

03

In context

Erythema

131 studies on the registry are indexed under Erythema; 17 are open to participants now.

This study's enrollment of 101 is above the median of 50 across 114 interventional studies indexed under Erythema.

Browse Erythema studies →

Lead sponsor

Galderma Brasil Ltda. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female research participants aged 18 or higher.
  2. Patients with chronic persistent facial erythema (at least 1 month before baseline [Day 1 hour 0]) of rosacea (with no restrictions to subtypes of rosacea), or originated from other dermatological condition, including, but not limited to seborrhoeic dermatitis, ulerythema ophryogenes, keratosis pillaris, microneedling, fractional radiofrequency, post-peeling treatments (medium depth and deep) or post-laser (ablative laser). Diagnosis is based on the investigator clinical judgement.
  3. Clinician Erythema Assessment scores 2 (mild), 3 (moderate), or 4 (severe) at Day 1 prior to study treatment administration.
  4. Patient Self-Evaluation scores 2 (mild), 3 (moderate), or 4 (severe) at Day 1 prior to study treatment administration.
  5. Female patients with and negative pregnancy test at baseline. These patients should use a highly efficient method during the study: combined oral contraceptives (estrogen and progesterone) or implanted contraceptives, or injectable contraceptives (with a stable dose for at least 1 month before study enrolment), bilateral tube ligation, hormonal intrauterine device (inserted at least 1 month before study entry), strict abstinence (at least 1 month prior to study entry and agreement in continuing throughout the study), or vasectomized partner (at least 3 months prior to study entry).
  6. Female patients without childbearing potential (e.g., before menstruating, [absence of menstrual bleeding for 1 year prior to study entry], hysterectomy, or bilateral oophorectomy, less than one year after menopause).
  7. Patients willing and able to fulfill the protocol requirements and duration.
  8. Patients who understand and sign the Form at study inclusion, before any study procedure is carried out.

Exclusion criteria

Exclusion Criteria:

  • Any research participant that meets one or more of the following criteria is not eligible for the trial:
  1. Female patients who are pregnant, breastfeeding or planning for pregnancy.
  2. Current treatment with monoamine oxidase inhibitors, barbiturates, opiates, sedatives, systemic anesthetics or alpha agonists.
  3. Patients who started or changed their doses of tricyclic antidepressants, cardiac glycosides, beta-blockers or other anti-hypertensive agents, in the 3 months prior to study entry.
  4. Current diagnosis of Raynaud syndrome, thromboangiitis obliterans, orthostatic hypotension, severe cardiovascular disease, coronary or cerebral insufficiency, hepatic or renal failure, sclerodermia, Sjögren syndrome, or depression.
  5. Any chronic or severe uncontrolled disease or medical chronic which may interfere with the interpretation of the study results, or may present a significant healthcare risk to the patient, if he/she participates in the study in accordance with the investigator judgment. (e.g. endocrine tumors, chromocytomas, systemic diseases that cause vascular erythema).
  6. Known or suspected allergies or to any of the components of the study treatments, including the active substance of brimonidine tartrate (see summary of product characteristics).
  7. Patients who received, applied or ingested the following treatments in accordance with the time period specified before Day 1:

    • Topic facial treatments or procedures:

    Any dermatological/surgical facial procedure - 4 weeks. Immunomodulators (e.g. Methotrexate, Cyclosporin) - 4 weeks. Mirvaso® - 4 weeks.

    • Systemic treatments:

    Isotretinoin - 6 months. Immunomodulators - 90 days. Phototherapy - 4 weeks.

  8. Exposure to excessive ultraviolet radiation within a week before Day 1 visit.
  9. Presence of beard or excessive facial hair at Day 1, which interferes with the study treatment or study assessments and refusal to remove it during the study period.
  10. Patients who do not wish to abstain from the use of forbidden medication or excessive exposure to ultraviolet radiation during the study period.
  11. Vulnerable research participants (as deprived of freedom), in accordance with Section 1.61 of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use - ICH for Good Clinical Practices.
  12. Current participation in any other clinical study with a drug or device OR participation within 30 days prior to Day 1 OR in an exclusion period of a previous clinical study (when possible).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
101 participants (actual)

Study arms

  • Other
    Mirvaso® gel

    Mirvaso® gel (5 mg/g brimonidine tartrate)

    Drug: brimonidine tartrate

Interventions

06

What researchers measure

Primary outcomes

  1. Efficacy endpoints: Percentage of research participants with at least 1 degree of improvement from baseline in PSE on each moment of post-baseline evaluation

    • Facial Erythema based on the Patient self-Evaluation (PSE) evaluated by the research participant on Day 1 (Hour 0 and Hour 3), Day 29 (Hour 0 and Hour 3). All eligible research participants will receive Mirvaso® gel once daily for 4 weeks. The study will include 4 clinical visits: before Day 1, on Day 1, Day 29 and Week 6. * Within 5 days before Day 1, the research participant will have a screening visit for confirmation of eligibility. * On Day 1 and on Day 29, the research participant will have Mirvaso® gel applied, at the research site, and the evaluation will be conducted before application and 3 hours after application; * During Days 2-28, research participants will have Mirvaso® gel applied once daily, at home; No Mirvaso® gel will be applied after the visit on Day 29; • Unscheduled visits may be performed during the trial for any safety reason.

    Time frame: 1 year

  2. Percentage of research participants with at least 1 degree of improvement from baseline in CEA on each moment of post-baseline evaluation.

    • Facial Erythema based on the Clinician erythema assessment (CEA) evaluated by the investigator on Day 1 (Hour 0 and Hour 3), Day 29 (Hour 0 and Hour 3) . Clinician Erythema Assessment scores: 2 (mild), 3 (moderate), or 4 (severe) . All eligible research participants will receive Mirvaso® gel once daily for 4 weeks. The study will include 4 clinical visits: before Day 1, on Day 1, Day 29 and Week 6. * Within 5 days before Day 1, the research participant will have a screening visit for confirmation of eligibility. * On Day 1 and on Day 29, the research participant will have Mirvaso® gel applied, at the research site, and the evaluation will be conducted before application and 3 hours after application; * During Days 2-28, research participants will have Mirvaso® gel applied once daily, at home; No Mirvaso® gel will be applied after the visit on Day 29; * Unscheduled visits may be performed during the trial for any safety reason.

    Time frame: 1 year

Secondary outcomes

  1. Evaluate the efficacy of Mirvaso by the Patient Self Evaluation - PSE

    To evaluate the efficacy of Mirvaso in the treatment of chronic persistent vascular facial erythema, after 4 and 6 weeks of treatment, by the patient self evaluation

    Time frame: 1 year

  2. Evaluate the efficacy of Mirvaso by the clinician erythema assessment - CEA

    To evaluate the efficacy of Mirvaso in the treatment of chronic persistent vascular facial erythema, after 6 weeks of treatment, by the clinician erythema assessment.

    Time frame: 1 year

  3. Incidence of AEs. Evaluate the safety of Mirvaso

    To evaluate the safety of Mirvaso up to 6 weeks after beginning the treatment

    Time frame: 1 year

  4. Study Participant Satisfaction Questionnaire

    Research participants will fill the Study Participant Satisfaction Questionnaire at Hour 3 on Day 29 with 7 questions.

    Time frame: 1 year

  5. To evaluate the impact in the quality of life after 4 weeks of treatment with Mirvaso

    Variation in the overall score in DLQI from baseline visit to each moment of post-baseline evaluation Dermatology life quality Index (DLQI) Questionnaire on Hour 0 on Day 1 and on Hour 3 on Day 29. 10 questions to measure how much the skin problem affected the quality life.

    Time frame: 1 year

  6. Variation in the overall score in FRQ from baseline visit to each moment of post-baseline evaluation

    Variation in the overall score in FRQ from baseline visit to each moment of post-baseline evaluation Facial Redness Questionnaire (FRQ) on Hour 0 on Day 1 and on Hour 3 on Day 29. 12 questions to evaluate how much facial erythema (redness) is affecting life at the moment of answer.

    Time frame: 1 year

Other outcomes

  1. Instrumental Evaluation by Mexameter®

    Evaluation by Mexameter®, including Day 1 (Hour 0 and Hour 3), Day 29 (Hour 0 and Hour 3) and Week 6. The equipment measures the main components of skin color, melanin and hemoglobin (erythema). This evaluation will only be performed in research sites where the necessary equipment is available.

    Time frame: 1 year

07

Study locations

5 sites
  • Instituto de Dermatologia e Estética do Brasil Ltda
    Rio de Janeiro, RJ 22471003, Brazil
  • Centro Brasileiro de Estudos em Dermatologia
    Porto Alegre - RS, RS 91781200, Brazil
  • Clinica Drmatologica Dra. Laura Buratini Ltda.
    Botucatu, SP 18603-440, Brazil
  • Hosptial do Servidor Publico Municipal
    Sao Paulo, SP 04564000, Brazil
  • Fundação do ABC
    São Paulo, SP 09041-410, Brazil
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2016 to primary completion in Feb 2017, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2016
First posted
Aug 5, 2016
StartActual
Jun 13, 2016
Primary completionActual
Feb 8, 2017
CompletionActual
Feb 8, 2017
Last update
Apr 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02856919
Collaborators
Eurotrials Brasil Consultores Cientificos Ltda
Responsible party
Sponsor
First posted
Aug 5, 2016
Start date
Jun 13, 2016
Primary completion
Feb 8, 2017
Completion
Feb 8, 2017
Last update
Apr 6, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brimonidine

Start the discussion